Tag: daunorubicin

Final NICE green light for Pfizer’s Mylotarg

by Selina McKee | Nov 15, 2018 | News | 0

Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine, as an option for untreated de novo CD33-positive acute myeloid leukaemia (AML).

Jazz’ Vyxeos wins EU nod for certain acute myeloid leukaemias

by Selina McKee | Aug 29, 2018 | News | 0

Dublin, Ireland-based Jazz Pharmaceuticals will be celebrating news of European approval of its leukaemia drug Vyxeos.

Speedy review for Jazz’ high-risk AML chemo

by Selina McKee | Nov 6, 2017 | News | 0

Dublin, Ireland-based Jazz Pharmaceuticals’ Vyxeos is being given a speedy review in Europe as a treatment for certain types of high-risk acute myeloid leukemia (AML).